---
schema_version: "secwatch.filing_event.v1"
accession: "0001539497-21-001048"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2021-07-16T23:59:59+00:00"
generated_at: "2026-06-30T04:47:38.415615+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Bioxytran director Henry Esber resigns; Hana Chen-Walden appointed to board

## Summary
- Dr. Henry Esber resigned as director effective July 15, 2021, for medical reasons.
- Hana Chen-Walden, M.D., a Medical Advisory Board member, elected to fill the vacancy.
- Dr. Chen-Walden has 35+ years of regulatory experience; she will receive no cash compensation as director.

## SEC filing metadata
- accession: 0001539497-21-001048
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2021-07-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/0001539497-21-001048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/n2583-x7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001539497-21-001048
- JSON: https://secwatch.observer/filing/0001539497-21-001048.json
- Plain text: https://secwatch.observer/filing/0001539497-21-001048.txt

## Key facts
- Executive change
  Henry Esber resigned as Director at BIOXYTRAN, INC.
  - Action: resigned
  - Role: Director
  source text: Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/0001539497-21-001048-index.htm
- Executive change
  Hana Chen-Walden was elected as Director at BIOXYTRAN, INC.
  - Action: elected
  - Role: Director
  source text: The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/0001539497-21-001048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.